Posts Tagged ‘Montreal Heart Institute’


Monday, December 5th, 2011

Montreal, Canada, December 5, 2011
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world’s first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark procedure was performed by Dr. Jean Francois Tanguay, interventional cardiologist and coordinator of the Coronary Unit, as part of the ABSORB EXTEND clinical trial. This successful intervention was a first in North America.

Dr. Jean Francois Tanguay
Dr. Jean Francois Tanguay
Coronary Unit
Montreal Heart Institute

A breakthrough that could change the lives of patients The patient, a woman in her sixties, had suffered from chest pain for a number of months. She was diagnosed with a severe lesion to the heart main artery. She responded favorably to the procedure, was discharged after 24 hours and now, one month after, has regained a normal way of life with no more chest pain.

The investigational ABSORB bioresorbable vascular scaffold, developed by global healthcare company Abbott, is an innovative therapy that restores blood flow by opening a clogged vessel and providing support to the vessel while it heals. Once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolized until the device dissolves after approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. With no metal left behind, the vessel has the potential to return to a more natural state. After the device has been metabolized, the patient’s vessel is free to move, flex, pulsate and dilate similar to an untreated vessel.

For Dr. Jean Francois Tanguay, it was important to be part of this first intervention, since during his postdoctoral studies he worked on early models of bioresorbable vascular scaffolds. “Treatments for coronary artery disease have progressed tremendously from the days of balloon angioplasties and metal stents leading to improved clinical outcome in our patients,” said Dr. Tanguay, who is also an associate professor of Medicine at the Universite de Montreal. “By effectively opening up a blocked artery without leaving a permanent implant behind in the blood vessel, this bioresorbable vascular scaffold has the potential to revolutionize how we treat our patients.”

A revolution in the way we treat patients with coronary artery disease

This treatment is available in Canada as part of Abbott’s global ABSORB EXTEND clinical trial which is a significant milestone toward making this innovative technology available to heart disease patients in Canada. In Canada, the clinical trial is conducted at four centers, including the Montreal Heart Institute (Dr. Jean Francois Tanguay), Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Dr. Eric Larose), University of Ottawa Heart Institute (Dr. Marino Labinaz) and St. Michael’s Hospital in Toronto (Dr. Christopher E. Buller). The ABSORB EXTEND trial will enroll approximately 1,000 patients from up to 100 centers in Europe, Asia Pacific, Canada and Latin America.

The device is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. ABSORB has CE Mark and is authorized for sale in Europe. It is under clinical investigation around the world with more than 500 patients treated with the device.

>>>>>Read all the latest in our News Page.


Thursday, September 4th, 2008

Montreal - For the first time, a major international study has demonstrated that using a medication to lower high heart rate in patients with coronary artery disease and a heart rate above 70 beats per minute can significantly lessen - by 30 percent or more - the risk of those patients suffering major cardiovascular problems such as heart attacks, a finding which could change the medical management of the disease.

The Montreal Heart Institute led the Canadian portion of the study, which involved almost 11,000 patients in 33 countries on four continents. The much-anticipated study results were presented this week at the 2008 European Society of Cardiology Congress in Munich, Germany and published simultaneously in the medical journal The Lancet.

The study, called BEAUTIfUL, followed 10,917 patients who had known heart disease and evaluated whether using a medication, a selective heart rate lowering agent ivabradine, would help prevent them from developing serious cardiovascular events such as heart attacks. All the patients were already receiving the guideline-recommended cardiovascular therapy, including the use of antiplatelet agents (by 94% of the study patients), angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (91%), beta-blockers (87%), as well as lipid-lowering agents (76%).

The results showed there was a neutral effect overall in the study, but that using the drug to lower heart rate had a significantly positive impact on patients who started with an elevated resting heart rate, defined as greater than 70 beats per minute.

BEAUTIfUL data conclusively demonstrated that these patients with an elevated resting heart rate greater than 70 bpm are more likely to die or suffer another cardiovascular event than patients with a lower resting heart rate. The increase in risk is 34% for cardiovascular death, 46% for myocardial infarction (heart attack), 56% for heart failure and 38% for coronary revascularisation. In those patients, the addition of the heart rate-lowering treatment resulted in a 36 percent lowering of the risk of hospitalization for fatal and non-fatal myocardial infarction (p=0.001) and a 30 percent lowering of the risk of coronary revascularization (p=0.016).

“The results from BEAUTIfUL support the role of selectively reducing heart rate in patients with known coronary heart disease who have a baseline heart rate more than 70,” said Dr. Jean-Claude Tardif, the study‚Äôs Canadian lead investigator, member of the study steering committee, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. “What is most interesting about the results is that by lowering heart rate sufficiently in these patients we can indeed have the potential to reduce the incidence of cardiovascular events over and above what we can achieve with the best standard of care we have available right now.”

Ivabradine is not yet approved or available in Canada.

PRESS RELEASE - Sept. 3, 2008 -